Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.

Exclusion Criteria

• •1. Wearing scleral or contact lenses within the last month, or those who plan to start wearing scleral or contact lenses during the study.
• •2. Anticipate major changes in systemic GvHD management during study period.
• •3. Comorbidity with other severe or chronic eye conditions that in the judgment of the investigator will interfere with study assessments, such as but not limited to retinal detachment, recent ocular surgery, Bell's palsy, active trigeminal neuritis or trigeminal neuralgia.
• •4. Anticipate change of vision correction or anticipate any ocular procedures during study period.
• •5. A woman who is pregnant, nursing an infant, or planning a pregnancy.
• •6. A woman of childbearing potential who has a positive urine pregnancy test at Visit 1, or who does not use an adequate method of birth control throughout the study period.
• •7. Has a known adverse reaction and/or sensitivity to the study drug or its components.
• •8. Unwilling to cease the use of sunscreen on the forehead or eye area.
• •9. Intraocular pressure \>22 mm Hg at screening visit with or without ongoing glaucoma treatment.
• •10. Currently enrolled in an investigational drug or device study for chronic ocular GvHD.